In coordination with the Clinical Data Interchange Standards Consortium (CDISC), Coalition for Accelerating Standards and Therapies (CFAST), FDA, and TransCelerate BioPharma, Inc., KHI assembled a working group that helped define appropriate standards in the therapeutic area of diabetic kidney disease. KHI’s specific role was providing clinical and medical expertise.